SCHEMBL12635642

SCHEMBL12635642

CC(C)(C)OC(=O)N1CCN(c2cc(C#Cc3ccc(F)cc3)c(C(F)(F)F)nn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 1/20 0.41
▸ GPR119 Q8TDV5 6/20 0.40
▸ CKS1B P61024 2/20 0.40
▸ SKP1 P63208 2/20 0.40
▸ SKP2 Q13309 2/20 0.40
▸ MAP4K4 O95819 1/20 0.39
▸ GRM5 P41594 1/20 0.38
▸ GRM1 Q13255 1/20 0.38
▸ SMARCA2 P51531 1/20 0.38
▸ SMARCA4 P51532 1/20 0.38
▸ PBRM1 Q86U86 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GRIA1 P42261 1/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ EGLN2 Q96KS0 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ S1PR2 O95136 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955406 0.82 CKS1B (0.44) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL2961821 0.81 CKS1B (0.44) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL12635624 0.80 S1PR2 (0.46) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL12635629 0.80 GALR2 (0.46) GPR119CKS1BSKP1SKP2MEN1
SCHEMBL12635634 0.79 ABCB1 (0.41) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL12635651 0.78 GPR119 (0.53) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL12635646 0.77 DNMT3A (0.49) GPR119MEN1KMT2AKDM1A
SCHEMBL2960084 0.77 CKS1B (0.44) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL31037289 0.76 GPR119 (0.44) ADKGPR119MAP4K4SMARCA2SMARCA4
SCHEMBL2958371 0.75 CKS1B (0.55) GPR119CKS1BSKP1SKP2SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530474-B2 Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2013-09-10 — — US disclosed
US-8530474-B2 Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2013-09-10 — — US disclosed
EP-2310374-B1 SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2012-10-31 — — EP disclosed
US-20110112107-A1 SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS JANSSEN-CILAG S.A. (ES) 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112107-A1 SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS HTR6, HTR5A, HTR1A ADK 616/4885GPR119 110/4885CKS1B 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback